Your browser doesn't support javascript.
loading
[Multidisciplinary management of retinoblastoma: Experience in 37 eyes]. / Manejo multidisciplinario en retinoblastoma: experiencia en 37 ojos.
Ossandón, D; Zanolli, M; Pérez, V; Rojas, T; Quijarro, P; Kabalan, P; Alvarez, D; Varas, M.
Afiliação
  • Ossandón D; Departamento de Oftalmología, Hospital San Juan de Dios, Santiago, Chile.
  • Zanolli M; Departamento de Oftalmología, Hospital San Juan de Dios, Santiago, Chile. Electronic address: mario.zanolli@me.com.
  • Pérez V; Departamento de Oncología Pediátrica, Hospital San Juan de Dios, Santiago, Chile.
  • Rojas T; Departamento de Oftalmología, Hospital San Juan de Dios, Santiago, Chile.
  • Quijarro P; Departamento de Oncología Pediátrica, Hospital San Juan de Dios, Santiago, Chile.
  • Kabalan P; Departamento de Oncología Pediátrica, Hospital San Juan de Dios, Santiago, Chile.
  • Alvarez D; Departamento de Oncología Pediátrica, Hospital San Juan de Dios, Santiago, Chile.
  • Varas M; Departamento de Oncología Pediátrica, Hospital San Juan de Dios, Santiago, Chile.
Arch Soc Esp Oftalmol ; 90(2): 55-62, 2015 Feb.
Article em Es | MEDLINE | ID: mdl-25617906
OBJECTIVE: To report the results of the multidisciplinary management of patients with retinoblastoma, including survival, enucleation rate, and systemic chemoreduction success. METHODS: A retrospective study was conducted on 27 patients (37 eyes) diagnosed with retinoblastoma, and treated by a multidisciplinary team in San Juan de Dios Hospital. Demographic information, clinical characterization, survival, local and systemic treatments were included in the analysis. Patients treated with intra-arterial chemotherapy (IAC) were also reviewed. RESULTS: The study included14 male patients (52%). The median of age at presentation was 8 months (0.16-90). The median follow-up time was 33 ± 21 months. The diagnosis was made in 10 (37%) cases after 15 months old, with a median of 35 months (24-90). 17 (63%) patients had unilateral retinoblastoma, and 10 (37%) bilateral retinoblastoma. Leukocoria, isolated or associated with other signs, was the most frequent reason for referral (63%). Global enucleation rate was 57% (n=21), being the primary treatment in 15 (55%) patients. Enucleation rate in unilateral retinoblastoma was 76.5%, and for bilateral retinoblastoma, it was 60% for one eye and 10% for both. Systemic chemotherapy was prescribed in 17 (63%) patients, with a mean number of cycles of 5.3 ± 2.1. The overall success of chemoreduction and focal therapy in order to avoid external radiotherapy and/or enucleation was 68%. Three patients were treated with IAC as a salvage therapy, controlling the tumor in 2 patients at 6 months of follow-up. These are the first cases reported in Chile. Survival rate was 100%. CONCLUSION: Multidisciplinary management of retinoblastoma led to a survival rate and morbidity comparable with international reports.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Equipe de Assistência ao Paciente / Retinoblastoma / Neoplasias da Retina Tipo de estudo: Observational_studies / Risk_factors_studies Limite: Child / Child, preschool / Female / Humans / Infant / Male / Newborn Idioma: Es Revista: Arch Soc Esp Oftalmol Ano de publicação: 2015 Tipo de documento: Article País de afiliação: Chile País de publicação: Espanha

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Equipe de Assistência ao Paciente / Retinoblastoma / Neoplasias da Retina Tipo de estudo: Observational_studies / Risk_factors_studies Limite: Child / Child, preschool / Female / Humans / Infant / Male / Newborn Idioma: Es Revista: Arch Soc Esp Oftalmol Ano de publicação: 2015 Tipo de documento: Article País de afiliação: Chile País de publicação: Espanha